Back to search results
NCT06433622

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Enrolling by Invitation
Not specifiedAges 18+Observational
Lancaster General Hospital
~225 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:Repeat Thromboelastography with Platelet Mapping

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Repeat TEG
Measured over 1 hour after platelets given
+1 more outcome measured

Conditions

Traumatic Intracranial Hemorrhage

Explore related trials

Intracranial hemorrhage following injuryHelicoid peripapillary chorioretinal degenerationMaximum Amplitude (MA)

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Lindsey Perea, DO · PRINCIPAL_INVESTIGATOR · Penn Medicine Lancaster General Health

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥ 18 years of age who present with TICH meeting Brain Injury Guidelines (BIG) 2 or 3 head bleed criteria
Currently on antiplatelet medication on admission
Must have taken this antiplatelet medication within the past 48 hours prior to presentation
Patients who have AA and/or ADP inhibition of 70% or greater and Maximum Amplitude (MA) \<50 will then receive a platelet transfusion and a repeat TEG-PM 1hr after transfusion

Exclusion

Under 18 years of age
Have a known bleeding diatheses
Current therapeutic anticoagulation use
Do not know the time of their last antiplatelet medication dose
Patients or their proxy who are unable to provide consent
Patients with concomitant long bone fractures or solid organ injuries
Abbreviated Injury Scale (AIS) \>1 in body regions other than head because of concomitant long bone fracture or solid organ injury
Under 18 years of age

What this trial measures

  • Repeat TEG1 hour after platelets given

    Rate of reversed pathway inhibition on repeat thromboelastography with platelet mapping (TEG-PM) when platelets are administered to TICH patients who are on antiplatelet therapy prior to admission.

  • Repeat Head CTFrom the time of interventional platelet administration until the time of patient discharge from their index admission, assessed up to 100 weeks.

    Number of patients with improved platelet function on repeat TEG-PM and stability of TICH on subsequent CT scan.